# SPECIALTY GUIDELINE MANAGEMENT

# **JAKAFI** (ruxolitinib)

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### A. FDA-Approved Indications

- 1. Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
- 2. Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

## B. Compendial Uses

- 1. Symptomatic low-risk or intermediate-risk 1 myelofibrosis
- 2. Accelerated phase or blast phase myelofibrosis
- 3. Polycythemia vera in patients with inadequate response or loss of response to interferon therapy

All other indications are considered experimental/investigational and are not a covered benefit.

### II. CRITERIA FOR INITIAL APPROVAL

### A. Myelofibrosis

Authorization of 12 months may be granted for the treatment of myelofibrosis.

### B. Polycythemia Vera

Authorization of 12 months may be granted for the treatment of polycythemia vera to members who have had an inadequate response or intolerance to hydroxyurea or interferon therapy (ie, interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b).

## **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

### **IV. REFERENCES**

- 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation; March 2016.
- 2. National Comprehensive Cancer Network. The NCCN Drugs & Biologics Compendium. http://www.nccn.org. Accessed August 23, 2017.

Jakafi SGM P2017

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference	number
1999-A	

 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.2018. https://www.nccn.org/professionals/physician\_gls/PDF/mpn.pdf. Accessed August 28, 2017.

Jakafi SGM P2017

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2017 CVS Caremark. All rights reserved.

**CVS** caremark<sup>™</sup>

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of